FDA again declines to approve Capricor’s Duchenne drug deramiocel, and Capricor disputes the agency’s reading of HOPE-3. Merck reports better overall survival with Kelun’s sacituzumab tirumotecan in advanced gastroesophageal cancer, while progression-free survival missed and the survival gain remains undisclosed. The roundup covers AstraZeneca’s sonesitatug vedotin priority review, PMV’s rezatapopt ovarian cancer data, Erasca’s ERAS-0015 pancreatic cancer plans and Germany’s ruling on Merck’s Keytruda SC. Also covered are Savara’s molgramostim review delay, J&J’s Tremfya (guselkumab) findings in axial psoriatic arthritis, CMS’s Medicare Advantage Part B proposal and FDA’s new biologics safety council.Delayed edition for Friday, November 20, 2026.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →